Heron Therapeutics, headquartered in San Diego, develops pharmaceuticals for acute and oncology care, employing 203 people. Their products include SUSTOL and CINVANTI for chemotherapy-related nausea and ZYNRELEF for pain management.
Heron Therapeutics (HRTX) reported a negative EPS surprise in its most recent quarterly earnings. For the most recent quarter, Heron Therapeutics's actual EPS was -$0.06, missing the estimate of -$0.04 per share, resulting in a -47.06% surprise.
📡️ Health Care
Earnings Surprise
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
